Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Aligos Therapeutics (ALGS) Invested Capital (2021 - 2025)

Aligos Therapeutics' Invested Capital history spans 5 years, with the latest figure at $53.5 million for Q4 2025.

  • For Q4 2025, Invested Capital rose 284.81% year-over-year to $53.5 million; the TTM value through Dec 2025 reached $53.5 million, up 284.81%, while the annual FY2025 figure was $53.5 million, 284.81% up from the prior year.
  • Invested Capital reached $53.5 million in Q4 2025 per ALGS's latest filing, down from $71.8 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $217.0 million in Q3 2021 to a low of -$29.0 million in Q4 2024.
  • Average Invested Capital over 5 years is $103.7 million, with a median of $97.0 million recorded in 2023.
  • Peak YoY movement for Invested Capital: tumbled 131.47% in 2024, then soared 284.81% in 2025.
  • A 5-year view of Invested Capital shows it stood at $184.7 million in 2021, then tumbled by 43.76% to $103.9 million in 2022, then decreased by 11.38% to $92.1 million in 2023, then plummeted by 131.47% to -$29.0 million in 2024, then skyrocketed by 284.81% to $53.5 million in 2025.
  • Per Business Quant, the three most recent readings for ALGS's Invested Capital are $53.5 million (Q4 2025), $71.8 million (Q3 2025), and $101.9 million (Q2 2025).